Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Mar Drugs
2023 Oct 29;2111:. doi: 10.3390/md21110568.
Show Gene links
Show Anatomy links
Comparative Assessment of APTT Reagents for Evaluating Anticoagulant Sensitivity of Fucosylated Glycosaminoglycans (FGs) Derived from Sea Cucumbers.
Sun H
,
Yang S
,
Li P
,
Shang X
,
Wang P
,
Zhang J
,
Yuan L
,
Yin R
,
Gao N
,
Zhao J
.
Abstract
Fucosylated glycosaminoglycans (FGs) derived from sea cucumbers exhibit potent intrinsic Xase (iXase) inhibition, anticoagulation, and antithrombosis. Plasma activated partial thromboplastin time (APTT), a widely used screening test worldwide, is crucial for evaluating anticoagulant efficacy. However, the applicability of these commercially available APTT reagents for assessing anticoagulation of FGs remains unreported. In this study, we investigated the disparity between ellagic acid and colloidal silica APTT reagents in evaluating anticoagulation of dHG-5 and dHLFG-4, two depolymerized FGs, and elucidated the underlying rationale. The results demonstrated that dHG-5 and dHLFG-4 exhibited heightened sensitivity to the ellagic acid APTT reagent both in vitro and in vivo, and did not significantly affect the activation of APTT reagents for plasma. In addition, both ellagic acid and colloidal silica APTT reagents inhibited the anti-iXase of dHG-5 and dHLFG-4, and the inhibition of the ellagic acid APTT reagent was less pronounced compared to the colloidal silica APTT reagent. These findings suggest that the reduced impact of the ellagic acid APTT reagent on the anti-iXase activity of dHG-5 and dHLFG-4 is responsible for the increased sensitivity in plasma APTT analysis. This study offers valuable insights into the characteristics of two APTT reagents applied for assessing the anticoagulant activity of FG-related compounds.
Beristain-Covarrubias,
Understanding Infection-Induced Thrombosis: Lessons Learned From Animal Models.
2019,
Pubmed
Bjornsson,
Variability in heparin sensitivity of APTT reagents.
1986,
Pubmed
Cai,
Precise structures and anti-intrinsic tenase complex activity of three fucosylated glycosaminoglycans and their fragments.
2019,
Pubmed
,
Echinobase
Chen,
Structural characterization of oligosaccharides from free radical depolymerized fucosylated glycosaminoglycan and suggested mechanism of depolymerization.
2021,
Pubmed
Donnellan,
Cancer and Venous Thromboembolic Disease: A Review.
2017,
Pubmed
Eikelboom,
Monitoring unfractionated heparin with the aPTT: time for a fresh look.
2006,
Pubmed
Falanga,
Deep vein thrombosis in cancer: the scale of the problem and approaches to management.
2005,
Pubmed
Gerotziafas,
Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
2007,
Pubmed
Goeijenbier,
Review: Viral infections and mechanisms of thrombosis and bleeding.
2012,
Pubmed
Gosselin,
Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
2015,
Pubmed
Harter,
Anticoagulation drug therapy: a review.
2015,
Pubmed
Hill,
Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance.
2007,
Pubmed
Javot,
Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio.
2009,
Pubmed
Kitchen,
Lipid composition of seven APTT reagents in relation to heparin sensitivity.
1999,
Pubmed
Kumano,
APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent.
2012,
Pubmed
Li,
Low-molecular-weight fucosylated glycosaminoglycan and its oligosaccharides from sea cucumber as novel anticoagulants: A review.
2021,
Pubmed
,
Echinobase
Lin,
From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors.
2020,
Pubmed
Manzato,
Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
1998,
Pubmed
Marlar,
Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies.
1984,
Pubmed
Pinto,
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
2017,
Pubmed
Pomin,
Holothurian fucosylated chondroitin sulfate.
2014,
Pubmed
,
Echinobase
Quan,
Factor XIa Inhibitors as New Anticoagulants.
2018,
Pubmed
Robert,
Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors.
2008,
Pubmed
Rosén,
FIX potency of rFIX-Albumin fusion protein is underestimated by one-stage methods using silica-based APTT reagents.
2020,
Pubmed
Shetty,
Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
2003,
Pubmed
Sun,
The components and activities analysis of a novel anticoagulant candidate dHG-5.
2020,
Pubmed
,
Echinobase
Tanaka,
[Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area].
2013,
Pubmed
Tripodi,
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.
2004,
Pubmed
Ts'ao,
Performance characteristics of a new synthetic APTT reagent.
1998,
Pubmed
Wada,
The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay.
2021,
Pubmed
Wang,
Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.
2010,
Pubmed
White,
The partial thromboplastin time: defining an era in coagulation.
2003,
Pubmed
Yasui,
Comparative analysis on characteristics of two activated partial thromboplastin time reagents.
2022,
Pubmed
Zhao,
Structure and anticoagulant activity of fucosylated glycosaminoglycan degraded by deaminative cleavage.
2013,
Pubmed
,
Echinobase
Zhou,
Effects of Native Fucosylated Glycosaminoglycan, Its Depolymerized Derivatives on Intrinsic Factor Xase, Coagulation, Thrombosis, and Hemorrhagic Risk.
2020,
Pubmed
,
Echinobase
